psoriatic%20arthritis
PSORIATIC ARTHRITIS
Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.

Principles of Therapy

  • Treatment should be initiated once psoriatic arthritis is diagnosed in order to alleviate the manifestations, prevent structural damage, delay disease progression, & maximize the quality of life

Pharmacotherapy

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

  • Provide good short-term symptomatic relief for patients w/ mild psoriatic arthritis
  • Do not inhibit the development of structural joint damage
  • Lowest effective dose of NSAID or COX-2 selective inhibitor should be given for the shortest duration in controlling symptoms due to the potential cardiotoxicity

Corticosteroids

  • Good symptomatic relief for mild psoriatic arthritis but corticosteroids cannot inhibit joint damage
  • Intra-articular corticosteroids are used for persistent synovitis (eg monoarthritis or oligoarthritis) or for bridging therapy while waiting for the systemic treatment to take effect
    • Intra-articular corticosteroids can be used when only a few joints are involved
  • Studies showed no evidence to support the use of systemic corticosteroids in patients w/ peripheral psoriatic arthritis

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

  • Used for patients w/ moderate to severe psoriatic arthritis that is more extensive or aggressive disease, requiring more potent treatment
  • Choice of DMARD should be based on patient preference, severity of joint & skin diseases, efficacy, comorbidities, risks of adverse effects, cost of medication & monitoring
  • DMARD failure is considered if at least 1 DMARD has failed individually or in combination in an adequate therapeutic trial (treatment for ≥3 mth of w/c 2 mth is at standard target dose)

Apremilast

  • A treatment option for patients w/ active psoriatic arthritis
  • Studies have shown that patients showed less joint tenderness & swelling & better physical function while on Apremilast therapy
  • A cyclic adenoside monophosphate (cAMP)-specific phosphodiesterase type-4 (PDE-4) inhibitor that acts by suppressing pro-inflammatory mediators

Methotrexate

  • Primary DMARD in psoriatic arthritis
  • First-line therapy for patients w/ moderate to severe active psoriatic arthritis
  • Effective in treating skin & joint involvement
  • Studies showed reduction in joint swelling, tenderness & erythrocyte sedimentation rate
    • Patients given w/ Methotrexate also showed superior physician assessment of arthritis activity compared to the placebo group

Leflunomide

  • Selectively inhibits pyrimidine synthesis that targets activated T-lymphocytes
  • Recommended for treatment of active peripheral psoriatic arthritis

Sulfasalazine

  • Used as an alternative in treating peripheral psoriatic arthritis
  • Has modest efficacy in patients w/ psoriatic arthritis
  • There were statistically significant positive effects on patient & physician global assessment of disease activity

Cyclosporin

  • May be considered in patients w/ active arthritis unresponsive to at least 2 conventional DMARDs
  • Use is limited because of toxicity issues

Other Disease-Modifying Anti-Rheumatic Drugs

  • Further studies are needed to prove efficacy of gold salts, Azathioprine, & d-Penicillamine for the treatment of psoriatic arthritis

Tumor Necrosis Factor (TNF) Inhibitors

  • Inhibit the pro-inflammatory cytokine involved in inflammation of the skin, synovium & joint fluid
  • Considered also as first-line treatment of moderate to severe active psoriatic arthritis
  • Recommended for treatment of active psoriatic arthritis in patients who are unresponsive or intolerant to at least 2 DMARDs or 1 DMARD w/ poor prognostic factors
  • More expensive compared w/ DMARDs but more cost-effective when used for a long period
  • Provide the following long-term benefits:
    • Decreased need for joint replacement surgery
    • Reduced demands on medical, nursing, & therapy services
    • Reduced needs for other medicines
    • Decreased demands on social services & careers
    • Improved quality of life
    • Increased probability of maintaining work
    • Increased life expectancy
  • TNF inhibitors have equal efficacy & similar adverse reactions
  • Choice of TNF blocker to use is individualized, taking into account the degree & severity of skin involvement
    • Other factors to consider are cost, patient preference, & physician preference 
  • Most clinicians use the combination of TNF inhibitor & Methotrexate as the standard care for the treatment of psoriatic arthritis
  • FDA warns physicians & the public of reports on the occurrence of hepatosplenic T-cell lymphoma, a rare malignancy, in patients receiving TNF inhibitors (eg Adalimumab, Etanercept, Golimumab)

Adalimumab

  • Effective in the treatment of moderate to severe peripheral psoriatic arthritis
  • Studies showed significant benefits such as better response rates, decreased radiographic progression of hand & foot joint disease & improvement in disability

Etanercept

  • Effective in treating moderate to severe peripheral psoriatic arthritis
  • Studies showed improvement in signs & symptoms such as decrease in number of tender joints, swollen joints, & morning stiffness
    • Also noted are decreased C-reactive protein levels, inhibition of radiographic disease progression & better physician & patient global ratings

Golimumab

  • Recommended for the treatment of active & progressive psoriatic arthritis
  • Studies showed statistically significant improvements in joint disease as compared to placebo

Infliximab

  • Effective in moderate to severe peripheral psoriatic arthritis
  • Studies showed better response rates, decreased dactylitis & enthesitis, & inhibition of radiographic disease progression

Ustekinumab

  • A human monoclonal antibody that targets IL-12 & IL-23
  • Recently approved by the FDA for the treatment of adult patients w/ active psoriatic arthritis
  • May be used alone or in combination w/ Methotrexate
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.